

68Ga-PSMA-11 PET/CT

Verification of Patient Eligibility for Expanded Access IND 131806

Patient Name:	Patient ID:
Gender:	Date of birth:
Referring Physician:	Ref Office Ph. #:

Indication for 68Ga-PSMA-11 PET/CT:

Suspected clinical recurrence of prostate cancer after initial radiation or surgical treatment, with evidence of biochemical failure.

Most recent prior PSA level Date:

Current PSA level Date:

Patient is treatment naive with respect to hormonal therapy.

Patient is a candidate for salvage therapy or systemic therapy depending on the PET/CT 68Ga-PSMA-11 identified location and extent of recurrence.

Prior Treatment: Radical/Prostatectomy Radiotherapy

Other relevant history:

For example: Current prostate cancer medications, initial Gleason Score

Is a contrast enhanced CT scan indicated/needed, independent of the 68Ga-PSMA-11 study? Yes No

Referring physician's clinical objectives for this diagnostic study?

Identify presence and location of locally recurrent disease in pelvis

Identify presence of metastatic systemic disease

Other

**NOTE: The cost of production of the 68Ga-PSMA-11 radiopharmaceutical is \$3,235. The patient will NOT be billed for the cost of the radiopharmaceutical (68Ga-PSMA-11). The patient is responsible for the technical charge for performance, estimated at (\$12,210) and professional analysis (\$593) for the PET/CT scan. The referring physician will need to obtain pre authorization from the patient's insurance to cover these expenses, based on clinical need.*

***A physician's order is required with the submission of this eligibility form. Please submit forms to ORI Scheduling orisched@iu.edu (preferred) or fax 317-274-8124.*

To be completed by Nuclear Medicine Physician:

Patient satisfies eligibility criteria of the Expanded Access IND: YES NO

NM Physician Digital Signature